Wedbush reissued their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Benzinga reports. Wedbush currently has a $110.00 target price on the biotechnology company’s stock. Several other equities analysts have also recently commented on the company. Needham & Company LLC reiterated a buy rating and set […]
Blueprint Medicines (BPMC) Buy Rating Reaffirmed at Needham & Company LLC theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
China Universal Asset Management Co. Ltd. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 353.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 7,032 shares of the biotechnology company’s stock after purchasing an additional 5,482 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Blueprint […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $1,000,582.77. Following the transaction, the director now directly owns 165,017 shares of the company’s stock, […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $1,000,582.77. Following the transaction, the director now directly owns 165,017 shares in […]